Page last updated: 2024-10-28

hydralazine and Eosinophilia-Myalgia Syndrome

hydralazine has been researched along with Eosinophilia-Myalgia Syndrome in 1 studies

Hydralazine: A direct-acting vasodilator that is used as an antihypertensive agent.
hydralazine : The 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent.

Eosinophilia-Myalgia Syndrome: A complex systemic syndrome with inflammatory and autoimmune components that affect the skin, fascia, muscle, nerve, blood vessels, lung, and heart. Diagnostic features generally include EOSINOPHILIA, myalgia severe enough to limit usual activities of daily living, and the absence of coexisting infectious, autoimmune or other conditions that may induce eosinophilia. Biopsy of affected tissue reveals a microangiopathy associated with diffuse inflammation involving connective tissue. (From Spitzer et al., J Rheumatol Suppl 1996 Oct;46:73-9; Blackburn WD, Semin Arthritis Rheum 1997 Jun;26(6):788-93)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Hess, EV1

Reviews

1 review available for hydralazine and Eosinophilia-Myalgia Syndrome

ArticleYear
Drug-related lupus.
    Current opinion in rheumatology, 1991, Volume: 3, Issue:5

    Topics: Antibodies, Antinuclear; Chlorpromazine; Drug Hypersensitivity; Eosinophilia-Myalgia Syndrome; Human

1991